Table 1.
Table 1Vaccine site treatment conditions by clinical trial
| Skin biopsy Sample ID |
N | Vaccine at VSME biopsy site |
# vaccines at VSME | Date of biopsy | Clinical trial | Study arm/group |
| Control: normal skin | 3 | None | 0 | 0 | Mel48 | 1A, 2A |
| IFA, w1 | 3 | IFA only | 1 | 7 | Mel48 | 1B |
| IFA+P, w1 | 5 | MELITAC 12.1+IFA | 1 | 7 | Mel48 | 2B |
| pICLC+P, w1 | 4 | MELITAC 12.1+polyICLC | 1 | 7 | Mel58 | 2A (V0) |
| pICLC+IFA+P, w1 | 4 | MELITAC 12.1+IFA+polyICLC | 1 | 7 | Mel58 | 2C (V6) |
| IFA, w3 | 4 | IFA only | 3 | 22 | Mel48 | 1C |
| IFA+P, w3 | 4 | MELITAC 12.1+IFA | 3 | 22 | Mel48 | 2C |
| Total | 27 |
Number of evaluated samples with each vaccine site treatment condition.
IFA, incomplete Freund’s adjuvant; p, peptide; pICLC, poly ICLC; w1, week 1; w3, week 3.